Browsing Tag
VEGF
4 posts
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema.
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as…